Not exact matches
For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial
of JCAR015 in adult patients with
relapsed or refractory B - cell
acute lymphoblastic leukemia due to patient deaths.
After seeing promising results in phase 1
of the Pediatric
Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50
Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent
of patients with
relapsed or refractory
acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50
leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate
of relapse, which is about 50 percent.
Ninety percent
of children and adults with
acute lymphoblastic leukemia (ALL) who had
relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School
of Medicine at the University
of Pennsylvania.
In 2014, the FDA approved Amgen's BLINCYTO ® (blinatumumab), the first BiTE ® therapy to receive FDA approval, for the treatment
of Philadelphia chromosome - negative
relapsed or refractory B - cell precursor
acute lymphoblastic leukemia, a rare and rapidly progressing cancer
of the blood and bone marrow.
Relapsed or refractory chronic lymphocytic
leukemia and
acute lymphoblastic leukemia patients have shown durable responses
of almost 2 years to a novel T - cell engineering technique developed at the University
of Pennsylvania Perelman School
of Medicine in Philadelphia.
Other CAR T - cell therapies approved in 2017 include tisagenlecleucel for the treatment
of children and young adults up to 25 years
of age with
relapsed or refractory B - cell precursor
acute lymphoblastic leukemia and axicabtagene ciloleucil (aci - cel; Yescarta) for adults with
relapsed or refractory DLBCL.
A phase I / II trial
of KTE - C19 (anti-CD19 CAR T cells) for pediatric and adolescent subjects with
relapsed / refractory B - precursor
acute lymphoblastic leukemia -LRB-
In a patient with
relapsed B - cell
acute lymphoblastic leukemia, a single dose
of 5 × 10 (4) / kg 1928zT2 T cells resulted in robust expansion and
leukemia eradication and led to complete remission.